Development of a vaccine against Staphylococcus aureus based on novel targets

传染病仍然是世界各地的主要杀手。医院获得性感染的增加和抗生素耐药性超级细菌是英国医疗保健系统的持续威胁。其中最重要的超级细菌是MRSA（耐甲氧西林金黄色葡萄球菌）。MRSA是S.金黄色。所有鼠伤寒沙门金黄色葡萄球菌菌株，包括MRSA，可以生活在人类的鼻子，这形成了一个理想的水库，从感染病人。这也使得从人类环境中根除这些生物变得非常困难。为了解决持续的医疗保健问题，需要新的策略，包括抗生素和疫苗。目前还没有针对MRSA和其他S.金黄色葡萄球菌菌株可用。接种疫苗的主要患者群体是透析患者、择期手术患者和糖尿病患者。其他人可能包括长期护理/疗养院的居民。一种有效的疫苗将对减少疾病负担和结果产生重大影响，并减少相关的人力和财力成本。拟议项目的目的是生产第一种针对MRSA和其他金黄色葡萄球菌菌株的疫苗。我们已经确定并申请了新的专利S。金黄色葡萄球菌疫苗组分。这些成分由所有菌株制成，并且是生物体引起疾病和/或生长的能力所必需的。因此，有机体离不开它们。最重要的是，我们已经证明，用这些成分进行的实验性疫苗接种可以预防沙门氏菌。金黄色葡萄球菌感染。该项目的主要目标是开发我们的成分的最佳配方，以推进临床。其目的是测试组分和其他参数的组合，以选择最有效的制剂进行临床前安全性评价和人体临床试验。

Infectious disease is still a major killer around the world. The rise of hospital acquired infections and the antibiotic resistant superbugs are a constant threat to the UK healthcare system. Foremost amongst the superbugs is MRSA (Methicillin Resistant Staphylococcus aureus). MRSA is an antibiotic resistant variant of S. aureus. All S. aureus strain, including MRSA, can live in the noses of humans and this forms an ideal reservoir from which to infect patients. It also makes it very difficult to eradicate these organisms form the human environment. To address the ongoing healthcare problem, novel strategies including antibiotics and a vaccine and are needed. At present there is no vaccine against MRSA and other S. aureus strains available. The main patient groups for vaccination would be those on dialysis, elective surgery patients and diabetics. Others could include residents of long term care/nursing homes. An effective vaccine would have significant impact in reducing both disease burden and outcome, with associated reduction in human and financial costs. The aim of the proposed project is to produce the first vaccine against MRSA and other Staphylococcus aureus strains. We have identified and filed patents on novel S. aureus vaccine components. The components are made by all strains and are required for the ability of the organism to cause disease and/or grow. Thus the organism cannot do without them. Most importantly, we have shown that experimental vaccination with these components can protect against S. aureus infection. The key goal of the project is to develop the best formulation of our components to take forward to the clinic. The aim is to test combinations of the components and other parameters to select the most effective formulation to progress into pre-clinical safety evaluation and human clinical trials.